Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

ESMO26: Intismeran sets new benchmark in adjuvant melanoma | PharmaVoice

Pharma Tech

ESMO26: Intismeran sets new benchmark in adjuvant melanoma

Oct 27, 2026, 5:18 PM

Read Full Article → ESMO26: Intismeran sets new benchmark in adjuvant melanoma

ESMO26: Intismeran sets new benchmark in adjuvant melanoma

Translate article text

Choose a language and wait for the translated text.

One notable finding from the INTerpath-001 trial, for which data was presented at ESMO 2026, was when the benefit appeared.